Evidence map›Paper›PMID 14966265›Full record

ArticleMolecular and cellular biology2004

ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage.

Ganesh R Panta, Swayamjot Kaur, Lakita G Cavin, Maria L Cortés, Frank Mercurio, Leonard Lothstein, Trevor W Sweatman, Mervyn Israel, Marcello Arsura

Open access · greenAbstract read
In one paragraph

Article in Molecular and cellular biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.

0numbers the graph read from it
0cells of the map it votes in
53citing papers in PubMed
7.9field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

53 citing papers in PubMed, 126 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Portrait of inflammatory response to ionizing radiation treatment.Journal of inflammation (London, England) · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

Ganesh R PantaDepartment of Pharmacology, Center for Anticancer Drug Research, University of Tennessee Cancer Institute, College of Medicine, Memphis, Tennessee 38163, USA.
Swayamjot Kaur
Lakita G Cavin
Maria L Cortés
Frank Mercurio
Leonard Lothstein
Trevor W Sweatman
Mervyn Israel
Marcello Arsura
University of Tennessee Health Science Center · USBristol-Myers Squibb (Switzerland) · CHMassachusetts General Hospital · US

Funding

ROLE OF NF-KB IN TGF-B1 INDUCED APOPTOSIS OF HEPATOCYTESR01CA078616 · NCI · UNIVERSITY OF TENNESSEE HEALTH SCI CTR · PI ARSURA, MARCELLO · 2000 to 2005
$1.1M
NCI NIH HHS CA78616NCI NIH HHS CA78616-S1NCI NIH HHS R01 CA078616
6 · The paper itself

Abstract

We have identified a novel pathway of ataxia telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK) signaling that results in nuclear factor kappaB (NF-kappaB) activation and chemoresistance in response to DNA damage. We show that the anthracycline doxorubicin (DOX) and its congener N-benzyladriamycin (AD 288) selectively activate ATM and DNA-PK, respectively. Both ATM and DNA-PK promote sequential activation of the mitogen-activated protein kinase (MAPK)/p90(rsk) signaling cascade in a p53-independent fashion. In turn, p90(rsk) interacts with the IkappaB kinase 2 (IKK-2) catalytic subunit of IKK, thereby inducing NF-kappaB activity and cell survival. Collectively, our findings suggest that distinct members of the phosphatidylinositol kinase family activate a common prosurvival MAPK/IKK/NF-kappaB pathway that opposes the apoptotic response following DNA damage.

Indexed as

DNA-Binding ProteinsDNA DamageAnimalsAntibiotics, AntineoplasticAtaxia Telangiectasia Mutated ProteinsCell Cycle ProteinsCell SurvivalDNA-Activated Protein KinaseDoxorubicinEnzyme ActivationEnzyme InhibitorsFibroblastsHumansI-kappa B KinaseMiceMitogen-Activated Protein Kinase KinasesAntibiotics, AntineoplasticAtaxia Telangiectasia Mutated ProteinsATM protein, humanAtm protein, mouseCell Cycle ProteinsCHUK protein, humanChuk protein, mouseDNA-Activated Protein KinaseDNA-Binding ProteinsDoxorubicinEnzyme InhibitorsI-kappa B KinaseIKBKB protein, humanIkbkb protein, mouseIKBKE protein, humanIkbke protein, mouseMitogen-Activated Protein Kinase KinasesNF-kappa BNuclear ProteinsPRKDC protein, humanProtein Serine-Threonine KinasesProtein SubunitsRibosomal Protein S6 Kinases, 90-kDaTumor Suppressor Protein p53Tumor Suppressor Proteins

Identifiers

PMID14966265
PMCPMC350545
OpenAlexW2105488316

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.